9 research outputs found
Lens magnification by CL0024+1654 in the U and R band
[ABRIDGED] We estimate the total mass distribution of the galaxy cluster
CL0024+1654 from the measured source depletion due to lens magnification in the
R band. Within a radius of 0.54Mpc/h, a total projected mass of
(8.1+/-3.2)*10^14 M_sol/h (EdS) is measured, which corresponds to a mass-
to-light ratio of M/L(B)=470+/-180. We compute the luminosity function of
CL0024+1654 in order to estimate contamination of the background source counts
from cluster galaxies. Three different magnification-based reconstruction
methods are employed using both local and non-local techniques. We have
modified the standard single power-law slope number count theory to incorporate
a break and applied this to our observations. Fitting analytical magnification
profiles of different cluster models to the observed number counts, we find
that the cluster is best described either by a NFW model with scale radius
r_s=334+/-191 kpc/h and normalisation kappa_s=0.23+/-0.08 or a power-law
profile with slope xi=0.61+/-0.11, central surface mass density
kappa_0=1.52+/-0.20 and assuming a core radius of r_core=35 kpc/h. The NFW
model predicts that the cumulative projected mass contained within a radius R
scales as M(<R)=2.9*10^14*(R/1')^[1.3-0.5lg (R/1')] M_sol/h. Finally, we have
exploited the fact that flux magnification effectively enables us to probe
deeper than the physical limiting magnitude of our observations in searching
for a change of slope in the U band number counts. We rule out both a total
flattening of the counts with a break up to U_AB<=26.6 and a change of slope,
reported by some studies, from dlog N/dm=0.4->0.15 up to U_AB<=26.4 with 95%
confidence.Comment: 19 pages, 12 figures, submitted to A&A. New version includes more
robust U band break analysis and contamination estimates, plus new plot
Thomas-Fermi Calculations of Atoms and Matter in Magnetic Neutron Stars II: Finite Temperature Effects
We present numerical calculations of the equation of state for dense matter
in high magnetic fields, using a temperature dependent Thomas-Fermi theory with
a magnetic field that takes all Landau levels into account. Free energies for
atoms and matter are also calculated as well as profiles of the electron
density as a function of distance from the atomic nucleus for representative
values of the magnetic field strength, total matter density, and temperature.
The Landau shell structure, which is so prominent in cold dense matter in high
magnetic fields, is still clearly present at finite temperature as long as it
is less than approximately one tenth of the cyclotron energy. This structure is
reflected in an oscillatory behaviour of the equation of state and other
thermodynamic properties of dense matter and hence also in profiles of the
density and pressure as functions of depth in the surface layers of magnetic
neutron stars. These oscillations are completely smoothed out by thermal
effects at temperatures of the order of the cyclotron energy or higher.Comment: 37 pages, 17 figures included, submitted to Ap
Neutrino opacity in magnetised hot and dense nuclear matter
We study the neutrino interaction rates in hot matter at high densities in
the presence of uniform magnetic field. The neutrino cross-sections involving
both the charged current absorption and neutral current scattering reactions on
baryons and leptons have been considered. We have in particular considered the
interesting case when the magnetic field is strong enough to completely
polarise the protons and electrons in supernovae and neutron stars. The opacity
in such a situation is considerably modified and the cross-section develops
anisotropy. This has implications for phenomenon invoked in the literature to
explain the observed pulsar kicks.Comment: 22 latex pages and 7 postscript figure
Radial Oscillations of Neutron Stars in Strong Magnetic Fields
The eigen frequencies of radial pulsations of neutron stars are calculated in
a strong magnetic field. At low densities we use the magnetic BPS equation of
state(EOS) similar to that obtained by Lai and Shapiro while at high densities
the EOS obtained from the relativistic nuclear mean field theory is taken and
extended to include strong magnetic field. It is found that magnetised neutron
stars support higher maximum mass where as the effect of magnetic field on
radial stability for observed neutron star masses is minimal.Comment: latex2e file with five postscript figure
Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset
Funding Information: Funding The study was funded by NORDFORSK (grant agreement no. 90825, project NORA), the Swedish Research Council (2018-02803), the Swedish innovation Agency (Vinnova), Innovationsfonden and The Research Council of Norway, Region Stockholm-Karolinska Institutet and Region VĂ€sterbotten (ALF), the Danish Rheumatism Association (R194-A6956), the Swedish Brain Foundation, Nils and Bibbi Jensens Foundation, the Knut and Alice Wallenberg Foundation, Margaretha af Ugglas Foundation, the South-Eastern Heath Region of Norway, the Health Research Fund of Central Denmark Region, Region of Southern Denmark, the A.P. Moller Foundation for the Advancement of Medical Science, the Colitis-Crohn Foreningen, the Novo Nordisk Foundation (NNF15OC0016932), Aase og Ejnar Danielsens Fond, Beckett-Fonden, Augustinus Fonden, Knud and Edith Eriksens Mindefond, Laege Sofus Carl Emil Friis and Hustru Olga Doris Friisâ Legat, the Psoriasis Forskningsfonden, the University of Aarhus, the Danish Rheumatism Association (R194-A6956, A1923, A3037 and A3570 â www. gigtforeningen.dk), Region of Southern Denmarkâs PhD Fund, 12/7725 (www.regionsyddanmark.dk) and the Department of Rheumatology, Frederiksberg Hospital (www.frederiksberghospital. dk). MoBa Genetics has been funded by the Research Council of Norway (#229624, #223273), South East and Western Norway Health Authorities, ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond Mohn Foundation, the Novo Nordisk Foundation and the University of Bergen. KB and SB acknowledge the Novo Nordisk Foundation (grant NNF14CC0001). Funding Information: competing financial interests as employees. OAA is a consultant to HealthLytix. The following coauthors report the following but unrelated to the current report: Karolinska Institutet, with JA as principal investigator, has entered into agreements with the following entities, mainly but not exclusively for safety monitoring of rheumatology immunomodulators: Abbvie, BMS, Eli Lilly, Janssen, MSD, Pfizer, Roche, Samsung Bioepis and Sanofi, unrelated to the present study. SB has ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S and managing board memberships in Proscion A/S and Intomics A/S. BG has received research grants from AbbVie, Bristol Myers-Squibb and Pfizer; OH has received research grants from AbbVie, Novartis and Pfizer, DVJ has received speaker and consultation fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB, AGL has received speaking and/or consulting fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB; and CT has received consulting fees from Roche, speaker fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Publisher Copyright: © Funding Information: Funding The study was funded by NORDFORSK (grant agreement no. 90825, project NORA), the Swedish Research Council (2018-02803), the Swedish innovation Agency (Vinnova), Innovationsfonden and The Research Council of Norway, Region Stockholm-Karolinska Institutet and Region VĂ€sterbotten (ALF), the Danish Rheumatism Association (R194-A6956), the Swedish Brain Foundation, Nils and Bibbi Jensens Foundation, the Knut and Alice Wallenberg Foundation, Margaretha af Ugglas Foundation, the South-Eastern Heath Region of Norway, the Health Research Fund of Central Denmark Region, Region of Southern Denmark, the A.P. Moller Foundation for the Advancement of Medical Science, the Colitis-Crohn Foreningen, the Novo Nordisk Foundation (NNF15OC0016932), Aase og Ejnar Danielsens Fond, Beckett-Fonden, Augustinus Fonden, Knud and Edith Eriksens Mindefond, Laege Sofus Carl Emil Friis and Hustru Olga Doris Friisâ Legat, the Psoriasis Forskningsfonden, the University of Aarhus, the Danish Rheumatism Association (R194-A6956, A1923, A3037 and A3570 â www. gigtforeningen.dk), Region of Southern Denmarkâs PhD Fund, 12/7725 (www.regionsyddanmark.dk) and the Department of Rheumatology, Frederiksberg Hospital (www.frederiksberghospital. dk). MoBa Genetics has been funded by the Research Council of Norway (#229624, #223273), South East and Western Norway Health Authorities, ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond Mohn Foundation, the Novo Nordisk Foundation and the University of Bergen. KB and SB acknowledge the Novo Nordisk Foundation (grant NNF14CC0001). Funding Information: competing financial interests as employees. OAA is a consultant to HealthLytix. The following coauthors report the following but unrelated to the current report: Karolinska Institutet, with JA as principal investigator, has entered into agreements with the following entities, mainly but not exclusively for safety monitoring of rheumatology immunomodulators: Abbvie, BMS, Eli Lilly, Janssen, MSD, Pfizer, Roche, Samsung Bioepis and Sanofi, unrelated to the present study. SB has ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S and managing board memberships in Proscion A/S and Intomics A/S. BG has received research grants from AbbVie, Bristol Myers-Squibb and Pfizer; OH has received research grants from AbbVie, Novartis and Pfizer, DVJ has received speaker and consultation fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB, AGL has received speaking and/or consulting fees from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB; and CT has received consulting fees from Roche, speaker fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Publisher Copyright: ©Objectives To find causal genes for rheumatoid arthritis (RA) and its seropositive (RF and/or ACPA positive) and seronegative subsets. Methods We performed a genome-wide association study (GWAS) of 31 313 RA cases (68% seropositive) and âŒ1 million controls from Northwestern Europe. We searched for causal genes outside the HLA-locus through effect on coding, mRNA expression in several tissues and/or levels of plasma proteins (SomaScan) and did network analysis (Qiagen). Results We found 25 sequence variants for RA overall, 33 for seropositive and 2 for seronegative RA, altogether 37 sequence variants at 34 non-HLA loci, of which 15 are novel. Genomic, transcriptomic and proteomic analysis of these yielded 25 causal genes in seropositive RA and additional two overall. Most encode proteins in the network of interferon-Alpha/beta and IL-12/23 that signal through the JAK/STAT-pathway. Highlighting those with largest effect on seropositive RA, a rare missense variant in STAT4 (rs140675301-A) that is independent of reported non-coding STAT4-variants, increases the risk of seropositive RA 2.27-fold (p=2.1Ă10-9), more than the rs2476601-A missense variant in PTPN22 (OR=1.59, p=1.3Ă10-160). STAT4 rs140675301-A replaces hydrophilic glutamic acid with hydrophobic valine (Glu128Val) in a conserved, surface-exposed loop. A stop-mutation (rs76428106-C) in FLT3 increases seropositive RA risk (OR=1.35, p=6.6Ă10-11). Independent missense variants in TYK2 (rs34536443-C, rs12720356-C, rs35018800-A, latter two novel) associate with decreased risk of seropositive RA (ORs=0.63-0.87, p=10-9-10-27) and decreased plasma levels of interferon-Alpha/beta receptor 1 that signals through TYK2/JAK1/STAT4. Conclusion Sequence variants pointing to causal genes in the JAK/STAT pathway have largest effect on seropositive RA, while associations with seronegative RA remain scarce.Peer reviewe
A. Thorolfsson
We present numerical calculations of the equation of state for dense matter in high magnetic fields, using a temperature dependent Thomas-Fermi theory with a magnetic field that takes all Landau levels into account. Free energies for atoms and matter are also calculated as well as profiles of the electron density as a function of distance from the atomic nucleus for representative values of the magnetic field strength, total matter density, and temperature. The Landau shell structure, which is so prominent in cold dense matter in high magnetic fields, is still clearly present at finite temperature as long as it is less than approximately one tenth of the cyclotron energy. This structure is reflected in an oscillatory behaviour of the equation of state and other thermodynamic properties of dense matter and hence also in profiles of the density and pressure as functions of depth in the surface layers of magnetic neutron stars. These oscillations are completely smoothed out by thermal eff..
The implementation of reverse Kessler warm rain scheme for radar reflectivity assimilation using a nudging approach in New Zealand
Cognitive Framework for HIV-1 Protease Cleavage Site Classification Using Evolutionary Algorithm
Humoral Immune Response to SARS-CoV-2 in Iceland.
To access publisher's full text version of this article click on the hyperlink belowBackground: Little is known about the nature and durability of the humoral immune response to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Methods: We measured antibodies in serum samples from 30,576 persons in Iceland, using six assays (including two pan-immunoglobulin [pan-Ig] assays), and we determined that the appropriate measure of seropositivity was a positive result with both pan-Ig assays. We tested 2102 samples collected from 1237 persons up to 4 months after diagnosis by a quantitative polymerase-chain-reaction (qPCR) assay. We measured antibodies in 4222 quarantined persons who had been exposed to SARS-CoV-2 and in 23,452 persons not known to have been exposed.
Results: Of the 1797 persons who had recovered from SARS-CoV-2 infection, 1107 of the 1215 who were tested (91.1%) were seropositive; antiviral antibody titers assayed by two pan-Ig assays increased during 2 months after diagnosis by qPCR and remained on a plateau for the remainder of the study. Of quarantined persons, 2.3% were seropositive; of those with unknown exposure, 0.3% were positive. We estimate that 0.9% of Icelanders were infected with SARS-CoV-2 and that the infection was fatal in 0.3%. We also estimate that 56% of all SARS-CoV-2 infections in Iceland had been diagnosed with qPCR, 14% had occurred in quarantined persons who had not been tested with qPCR (or who had not received a positive result, if tested), and 30% had occurred in persons outside quarantine and not tested with qPCR.
Conclusions: Our results indicate that antiviral antibodies against SARS-CoV-2 did not decline within 4 months after diagnosis. We estimate that the risk of death from infection was 0.3% and that 44% of persons infected with SARS-CoV-2 in Iceland were not diagnosed by qPCR